COMMUNIQUÉS West-GlobeNewswire

PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
24/06/2025
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly-owned subsidiary PetVivo Animal Health, Inc. (collectively "PetVivo" or the “Company”) an emerging [...]
Lulutox Tea UK (Lulutox Tea Detox) Officially Launches in Ireland, USA, Australia & Canada for Natural Digestive Cleanse
24/06/2025
Lulutox Detox Tea officially launches across Ireland, the USA, UK, Australia and Canada. Formulated with natural herbs like dandelion, fennel, and peppermint to support digestion, detox, and gut health—naturally and [...]
Clariane place avec succès une émission obligataire de 400 millions d’euros
24/06/2025
Communiqué de presse Clariane place avec succès une émission obligataire de 400 millions d’euros Paris, le 24 juin 2025 – Clariane (CLARI.PA – ISIN FR0010386334), annonce aujourd’hui avoir placé avec succès une émission [...]
Clariane has successfully completed a bond issue of 400 million euros
24/06/2025
Press release June 24, 2025 Clariane has successfully completed a bond issue in the amount of 400 million euros Paris, June 24, 2025 – Clariane (CLARI.PA – ISIN FR0010386334), announces today that it has successfully [...]
CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
24/06/2025
Communiqué de presse CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension Opération portée à plus de 5,7 millions d’euros suite à [...]
CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
24/06/2025
Press release CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause Transaction raised to over 5.7 million euros following full exercise of the extension [...]
Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR)
24/06/2025
Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, [...]
Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation
24/06/2025
Strategic Offshore Manufacturing Move Expected to Drive Gross Margin Expansion, Free Up Working Capital, and Enhance Scalability Transition to Outsourced Production Reduces Fixed Costs and Supports Trinity’s Broader [...]
InnovAge PACE Sponsors Documentary Spotlighting National Crisis in Family Caregiving
24/06/2025
PBS “Caregiving” Documentary, featuring Actor Bradley Cooper, Premieres Tonight DENVER, June 24, 2025 (GLOBE NEWSWIRE) -- InnovAge, the nation’s largest provider of the Program of All-inclusive Care for the Elderly ( [...]
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
24/06/2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel [...]
OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities
24/06/2025
MINNEAPOLIS, June 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has [...]
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
24/06/2025
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
24/06/2025
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2025 (GLOBE NEWSWIRE [...]
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
24/06/2025
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives CAMBRIDGE, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing [...]
THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies
24/06/2025
Breakthrough Transaction Unites Segment Leaders into a Powerful and Flexible Player in the Legal Cannabis Industry MEDFORD, Ore., June 24, 2025 (GLOBE NEWSWIRE) -- THC Therapeutics, Inc. (“THCT” or the “Company”), (OTC [...]
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
24/06/2025
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, [...]
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
24/06/2025
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a [...]
Xenon Announces Appointment of Darren Cline as Chief Commercial Officer
24/06/2025
Mr. Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications VANCOUVER, British Columbia and [...]
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
24/06/2025
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on [...]

Pages